Results 51 to 60 of about 16,650 (226)

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1301-1302, June 2026.
Francesco Saccà, Ryan Pelto
wiley   +1 more source

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitor (ICI) therapies are known to cause immune‐related adverse events (irAEs), including life‐threatening myocarditis, myositis, and myasthenia (MMM) overlap syndrome. Current literature lacks established therapeutic guidelines for effective management with steroid‐sparing agents.
Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury, Ernest Algabre   +3 more
wiley   +1 more source

Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome

Clinical Neurophysiology Practice, 2018
Objective: To report the clinical features and the neurophysiological approach of a patient with Lambert-Eaton myasthenic syndrome (LEMS), highlighting the diagnostic role of the stimulated single fiber electromyography (sSFEMG).
Vincenzo Todisco, Giovanni Cirillo, Rocco Capuano, Alessandro d'Ambrosio, Gioacchino Tedeschi, Antonio Gallo   +5 more
doaj   +1 more source

Myasthenic crisis appearing after resection of intracardiac ectopic thymoma with superior vena cava syndrome

Surgical Case Reports, 2021
Background We describe herein an extremely rare case of intracardiac ectopic thymoma—only two pure cases have been reported to date—associated with myasthenia gravis, an infrequent complication of ectopic thymoma.
Satoshi Takebayashi, Yasuji Yoshikawa, Masato Morita, Ryotaro Nagashima, Yuichi Nakazono, Shinji Miyamoto   +5 more
doaj   +1 more source

Lambert-Eaton myasthenic syndrome [PDF]

Postgraduate Medical Journal, 1999
SummaryThe Lambert-Eaton myasthenic syndrome is a neuromuscular disorder characterised by defective neurotransmitter release at autonomic neurones and presynaptic terminals of the neuromuscular junction. It is caused by an IgG autoantibody formed against especially the P/Q type of voltage-gated calcium channels (VGCC) which is an essential component of
U, Seneviratne, R, de Silva
openaire   +2 more sources

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

First‐in‐Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle‐Specific Kinase Agonist Adimanebart (ARGX‐119)

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Adimanebart (ARGX‐119), a first‐in‐class, humanized, agonistic monoclonal antibody, specifically targets and activates muscle‐specific kinase, stabilizing the neuromuscular junction, increasing muscle strength, and decreasing muscle weakness and fatigability in nonclinical, proof‐of‐concept studies.
Tonke van Bragt, Christa Kneip, Sofie Priem, Xinghong Leng, Rachelle Mutch, Sonya K. Patel, Peter Vanhoenacker, Cristina Vaghi, Sven Hoefman, Rebecca Shilling, Roeland Vanhauwaert   +10 more
wiley   +1 more source

Clinical and genetic basis of congenital myasthenic syndromes

Arquivos de Neuro-Psiquiatria
Neuromuscular junction disorders represent a wide group of neurological diseases characterized by weakness, fatigability and variable degrees of appendicular, ocular and bulbar musculature involvement.
Paulo Victor Sgobbi de Souza, Gabriel Novaes de Rezende Batistella, Valéria Cavalcante Lino, Wladimir Bocca Vieira de Rezende Pinto, Marcelo Annes, Acary Souza Bulle Oliveira   +5 more
doaj   +1 more source

Congenital Myasthenic Syndrome with Agrin Mutations

Pediatric Neurology Briefs, 2014
Investigators at Newcastle University, UK, and Hopitaux de Paris, France, report 5 patients from 3 unrelated families with a strikingly homogeneous clinical entity combining congenital myasthenia with distal muscle weakness and atrophy resembling a ...
J Gordon Millichap, John J Millichap
doaj   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source